Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Monopar Therapeutics Inc.NASDAQ: MNPR
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities remains negative
Q1 FY2026 other current liabilities was $0, compared with $0 a year earlier.
Context
- Other current liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Current Liabilities vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
- Other current liabilities amounts to 0.0% of total assets for MNPR, versus a peer median of 5.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $57.7M USD | +513.1% | +142.1% | 19.8% | |
| Sep 2026 | $40.97M USD | +359.6% | +97.7% | 8.1% | |
| Jun 2026 | $27.36M USD | -45.6% | — | 3.8% | |
| Mar 2026 | $18.45M USD | — | -8.5% | 8.5% | |
| Mar 2026 | $11.11M USD | +74.0% | +45.1% | 6.2% | |
| Dec 2025 | €9.97M EUR | +30.4% | -19.4% | 15.9% | |
| Mar 2026 | $9.58M USD | -56.5% | +8.5% | 1.5% | |
| Mar 2026 | $1.19M USD | -20.6% | +19.9% | 0.6% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Jun 2026 | $0 USD | — | — | 0.0% | |
| Sep 2026 | -$11.93M USD | -141.7% | -15.5% | 1.0% | |
| Peer median (excluding MNPR) | — | +4.9% | +14.2% | 5.0% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.